Pushpa Patel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Pushpa Patel has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Paula M. Mendes
School of Chemical Engineering, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
3 shared publications - Alexandra Mazharian
Institut National de la Santé et de la Recherche Médicale Unité Mixte de Recherche - S 1255, Etablissement Français du Sang Grand Est, Université de Strasbourg
2 shared publications - Ana Vieira
Instituto Português de Oncologia de Lisboa Francisco Gentil, 1099-023 Lisbon, Portugal
2 shared publications Christopher W. Smith
Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
2 shared publications- Christos Papaneophytou
Department of Life Sciences, School of Life and Health Sciences, University of Nicosia, Nicosia 2417, Cyprus
2 shared publications - Dimitra Dionysiou
Institute of Communication and Computer Systems, National Technical University of Athens, Zografos Campus, 15780 Athens, Greece
2 shared publications
Latest Publications
- Open Access
- 2 October 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (19) , 8823
Circulating miRNAs and Multivariate Biomarker Signatures in Ovarian Cancer: A Systematic Review
Ovarian cancer (OC) is the most lethal gynecological malignancy, largely because non-specific symptoms contribute to advanced-stage diagnosis and poor prognosis, underscoring the need for improved non-invasive biomarkers. Circulating microRNAs (c-miRNAs) have emerged as promising candidates for OC detection, risk stratification, prognosis, and treatment monitoring. This systematic review, prospectively registered in PROSPERO (CRD420251230898), evaluated the diagnostic and prognostic performance of c-miRNAs and miRNA-based multivariate signatures. MEDLINE/PubMed, Scopus, and CENTRAL were searched from inception to 30 May 2026. Eligible studies assessed c-miRNAs in serum, plasma, whole blood, or extracellular vesicle fractions from women with confirmed or suspected OC including studies using prediagnostic samples from women subsequently diagnosed with OC. Records were screened, data extracted, and risk of bias evaluated according to the type of result using QUADAS-2 for diagnostic accuracy, QUIPS for prognostic-factor associations, and PROBAST for multivariable prediction models. Of 697 records identified, 91 publications met the inclusion criteria. Most studies used case–control or observational designs and analysed serum or plasma samples. Single c-miRNAs generally showed moderate diagnostic accuracy, whereas multivariate miRNA panels and multimodal models incorporating CA-125 or HE4 generally reported higher AUC values, including in some early-stage cohorts. Frequently reported candidates included members of the miR-200 family, miR-21, miR-1246, miR-125b, miR-145, miR-205, and miR-130a. Prognostic studies associated c-miRNAs with survival, recurrence, treatment response, and chemoresistance, although findings were more heterogeneous than diagnostic findings. Risk-of-bias concerns were common, particularly for patient selection in diagnostic studies, confounding in prognostic-factor analyses, and statistical analysis in prediction-model studies. Overall, c-miRNAs represent promising non-invasive biomarkers for OC, particularly when integrated into multivariate or multimodal models. However, methodological heterogeneity, small cohort sizes, limited external validation, and inconsistent reporting currently restrict clinical translation. Future studies should prioritize standardized pre-analytical and analytical workflows, adequately powered prospective cohorts, and independent multicenter validation.
- 2 October 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (19) , 8823
Open AccessCirculating miRNAs and Multivariate Biomarker Signatures in Ovarian Cancer: A Systematic Review
Ovarian cancer (OC) is the most lethal gynecological malignancy, largely because non-specific symptoms contribute to advanced-stage diagnosis and poor prognosis, underscoring the need for improved non-invasive biomarkers. Circulating microRNAs (c-miRNAs) have emerged as promising candidates for OC detection, risk stratification, prognosis, and treatment monitoring. This systematic review, prospectively registered in PROSPERO (CRD420251230898), evaluated the diagnostic and prognostic performance of c-miRNAs and miRNA-based multivariate signatures. MEDLINE/PubMed, Scopus, and CENTRAL were searched from inception to 30 May 2026. Eligible studies assessed c-miRNAs in serum, plasma, whole blood, or extracellular vesicle fractions from women with confirmed or suspected OC including studies using prediagnostic samples from women subsequently diagnosed with OC. Records were screened, data extracted, and risk of bias evaluated according to the type of result using QUADAS-2 for diagnostic accuracy, QUIPS for prognostic-factor associations, and PROBAST for multivariable prediction models. Of 697 records identified, 91 publications met the inclusion criteria. Most studies used case–control or observational designs and analysed serum or plasma samples. Single c-miRNAs generally showed moderate diagnostic accuracy, whereas multivariate miRNA panels and multimodal models incorporating CA-125 or HE4 generally reported higher AUC values, including in some early-stage cohorts. Frequently reported candidates included members of the miR-200 family, miR-21, miR-1246, miR-125b, miR-145, miR-205, and miR-130a. Prognostic studies associated c-miRNAs with survival, recurrence, treatment response, and chemoresistance, although findings were more heterogeneous than diagnostic findings. Risk-of-bias concerns were common, particularly for patient selection in diagnostic studies, confounding in prognostic-factor analyses, and statistical analysis in prediction-model studies. Overall, c-miRNAs represent promising non-invasive biomarkers for OC, particularly when integrated into multivariate or multimodal models. However, methodological heterogeneity, small cohort sizes, limited external validation, and inconsistent reporting currently restrict clinical translation. Future studies should prioritize standardized pre-analytical and analytical workflows, adequately powered prospective cohorts, and independent multicenter validation.
- Open Access
- 5 September 2026
- Published by MDPI AG in Applied Sciences
- Vol. 16 (17) , 8832
Integrating Circulating miRNA Profiles, Glycosylation, and Volatile Organic Compound Signatures Toward Multimodal Liquid Biopsy for Early Detection of Ovarian Cancer: A Molecular Framework
Ovarian cancer remains difficult to detect before dissemination, and individual circulating biomarkers are unlikely to capture its biological and clinical heterogeneity. Multimodal liquid biopsy offers a potential route forward, but most biomarker combinations are developed empirically, with limited consideration of the molecular relationships among the measured signals. In this Perspective, we propose that intracellular miRNA dysregulation may provide an organizing layer for integrating glycoprotein/glycan remodeling with blood-derived volatile organic compound (VOC) signatures, while corresponding circulating miRNA profiles constitute a distinct measurable biomarker layer that may only partially reflect the underlying intracellular regulatory state. The miRNA–glycosylation axis is supported by direct mechanistic evidence that selected miRNAs regulate glycogenes and pathways controlling fucosylation, sialylation, and other glycan features. By contrast, the proposed connection between miRNA dysregulation and VOC production is indirect and likely mediated through metabolic reprogramming, mitochondrial dysfunction, oxidative stress, ferroptosis, and lipid peroxidation. We evaluate the evidence supporting each biomarker domain, prioritize candidate bridge miRNAs, including members of the miR-200 family and miR-34a, and define the principal boundary conditions of the framework, including causal inference, disease specificity, histological heterogeneity, VOC source ambiguity, temporal variability, and cross-platform standardization. We further outline a translational strategy based on matched biospecimens, mechanism-aware computational integration, experimental perturbation, longitudinal analysis, and independent validation at clinically relevant specificity thresholds. The objective is not to assert a fixed causal chain, but to provide a testable, clinically oriented framework for moving multimodal ovarian cancer diagnostics from statistical combination to biologically informed integration.
- 5 September 2026
- Published by MDPI AG in Applied Sciences
- Vol. 16 (17) , 8832
Open AccessIntegrating Circulating miRNA Profiles, Glycosylation, and Volatile Organic Compound Signatures Toward Multimodal Liquid Biopsy for Early Detection of Ovarian Cancer: A Molecular Framework
Ovarian cancer remains difficult to detect before dissemination, and individual circulating biomarkers are unlikely to capture its biological and clinical heterogeneity. Multimodal liquid biopsy offers a potential route forward, but most biomarker combinations are developed empirically, with limited consideration of the molecular relationships among the measured signals. In this Perspective, we propose that intracellular miRNA dysregulation may provide an organizing layer for integrating glycoprotein/glycan remodeling with blood-derived volatile organic compound (VOC) signatures, while corresponding circulating miRNA profiles constitute a distinct measurable biomarker layer that may only partially reflect the underlying intracellular regulatory state. The miRNA–glycosylation axis is supported by direct mechanistic evidence that selected miRNAs regulate glycogenes and pathways controlling fucosylation, sialylation, and other glycan features. By contrast, the proposed connection between miRNA dysregulation and VOC production is indirect and likely mediated through metabolic reprogramming, mitochondrial dysfunction, oxidative stress, ferroptosis, and lipid peroxidation. We evaluate the evidence supporting each biomarker domain, prioritize candidate bridge miRNAs, including members of the miR-200 family and miR-34a, and define the principal boundary conditions of the framework, including causal inference, disease specificity, histological heterogeneity, VOC source ambiguity, temporal variability, and cross-platform standardization. We further outline a translational strategy based on matched biospecimens, mechanism-aware computational integration, experimental perturbation, longitudinal analysis, and independent validation at clinically relevant specificity thresholds. The objective is not to assert a fixed causal chain, but to provide a testable, clinically oriented framework for moving multimodal ovarian cancer diagnostics from statistical combination to biologically informed integration.
- Open Access
- 23 August 2024
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 8 (6) , 102557
LAIR-1 and PECAM-1 function via the same signaling pathway to inhibit GPVI-mediated platelet activation
- 23 August 2024
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 8 (6) , 102557
Open AccessLAIR-1 and PECAM-1 function via the same signaling pathway to inhibit GPVI-mediated platelet activation
- Open Access
- 16 July 2021
- Published by Taylor & Francis in Platelets
- Vol. 32 (8) , 1018-1030
Platelet activation by charged ligands and nanoparticles: platelet glycoprotein receptors as pattern recognition receptors
Charge interactions play a critical role in the activation of the innate immune system by damage- and pathogen-associated molecular pattern receptors. The ability of these receptors to recognize a wide spectrum of ligands through a common mechanism is critical in host defense. In this article, we argue that platelet glycoprotein receptors that signal through conserved tyrosine-based motifs function as pattern recognition receptors (PRRs) for charged endogenous and exogenous ligands, including sulfated polysaccharides, charged proteins and nanoparticles. This is exemplified by GPVI, CLEC-2 and PEAR1 which are activated by a wide spectrum of endogenous and exogenous ligands, including diesel exhaust particles, sulfated polysaccharides and charged surfaces. We propose that this mechanism has evolved to drive rapid activation of platelets at sites of injury, but that under some conditions it can drive occlusive thrombosis, for example, when blood comes into contact with infectious agents or toxins. In this Opinion Article, we discuss mechanisms behind charge-mediated platelet activation and opportunities for designing nanoparticles and related agents such as dendrimers as novel antithrombotics.
- 16 July 2021
- Published by Taylor & Francis in Platelets
- Vol. 32 (8) , 1018-1030
Open AccessPlatelet activation by charged ligands and nanoparticles: platelet glycoprotein receptors as pattern recognition receptors
Charge interactions play a critical role in the activation of the innate immune system by damage- and pathogen-associated molecular pattern receptors. The ability of these receptors to recognize a wide spectrum of ligands through a common mechanism is critical in host defense. In this article, we argue that platelet glycoprotein receptors that signal through conserved tyrosine-based motifs function as pattern recognition receptors (PRRs) for charged endogenous and exogenous ligands, including sulfated polysaccharides, charged proteins and nanoparticles. This is exemplified by GPVI, CLEC-2 and PEAR1 which are activated by a wide spectrum of endogenous and exogenous ligands, including diesel exhaust particles, sulfated polysaccharides and charged surfaces. We propose that this mechanism has evolved to drive rapid activation of platelets at sites of injury, but that under some conditions it can drive occlusive thrombosis, for example, when blood comes into contact with infectious agents or toxins. In this Opinion Article, we discuss mechanisms behind charge-mediated platelet activation and opportunities for designing nanoparticles and related agents such as dendrimers as novel antithrombotics.
- 17 August 2018
- Published by American Society of Hematology in Blood Advances
- Vol. 2 (16) , 2072-2078
TREM-like transcript 1: a more sensitive marker of platelet activation than P-selectin in humans and mice
Key Points: Platelet activation in vitro results in a more rapid and greater upregulation of TLT-1 surface expression compared with P-selectin. TLT-1 is more rapidly translocated to the surface of activated platelets than P-selectin during thrombus formation in vivo.
- 17 August 2018
- Published by American Society of Hematology in Blood Advances
- Vol. 2 (16) , 2072-2078
TREM-like transcript 1: a more sensitive marker of platelet activation than P-selectin in humans and mice
Key Points: Platelet activation in vitro results in a more rapid and greater upregulation of TLT-1 surface expression compared with P-selectin. TLT-1 is more rapidly translocated to the surface of activated platelets than P-selectin during thrombus formation in vivo.
- Open Access
- 6 February 2009
- Published by Springer Nature in Reproductive Biology and Endocrinology
- Vol. 7 (1) , 10
The endogenous production of hydrogen sulphide in intrauterine tissues
Background: Hydrogen sulphide is a gas signalling molecule which is produced endogenously from L-cysteine via the enzymes cystathionine beta-synthase (CBS) and cystathionine gamma-lyase (CSE). The possible role of hydrogen sulphide in reproduction has not yet been fully investigated. It has been previously demonstrated that hydrogen sulphide relaxes uterine smooth muscle in vitro. The aim of the present study was to investigate the endogenous production of hydrogen sulphide in rat and human intrauterine tissues in vitro. Methods: The production of hydrogen sulphide in rat and human intrauterine tissues was measured in vitro using a standard technique. The expression of CBS and CSE was also investigated in rat and human intrauterine tissues via Western blotting. Furthermore, the effects of nitric oxide (NO) and low oxygen conditions on the production rates of hydrogen sulphide were investigated. Results: The order of hydrogen sulphide production rates (mean +/- SD, n = 4) for rat tissues were: liver (777 +/- 163 nM/min/g) > uterus (168 +/- 100 nM/min/g) > fetal membranes (22.3 +/- 15.0 nM/min/g) > placenta (11.1 +/- 4.7 nM/min/g), compared to human placenta (200 +/- 102 nM/min/g). NO significantly increased hydrogen sulphide production in rat fetal membranes (P < 0.05). Under low oxygen conditions the production of hydrogen sulphide was significantly elevated in human placenta, rat liver, uterus and fetal membranes (P < 0.05). Western blotting (n = 4) detected the expression of CBS and CSE in all rat intrauterine tissues, and in human placenta, myometrium, amnion and chorion. Conclusion: Rat and human intrauterine tissues produce hydrogen sulphide in vitro possibly via CBS and CSE enzymes. NO increased the production of hydrogen sulphide in rat fetal membranes. The augmentation of hydrogen sulphide production in human intrauterine tissues in a low oxygen environment could have a role in pathophysiology of pregnancy.
- 6 February 2009
- Published by Springer Nature in Reproductive Biology and Endocrinology
- Vol. 7 (1) , 10
Open AccessThe endogenous production of hydrogen sulphide in intrauterine tissues
Background: Hydrogen sulphide is a gas signalling molecule which is produced endogenously from L-cysteine via the enzymes cystathionine beta-synthase (CBS) and cystathionine gamma-lyase (CSE). The possible role of hydrogen sulphide in reproduction has not yet been fully investigated. It has been previously demonstrated that hydrogen sulphide relaxes uterine smooth muscle in vitro. The aim of the present study was to investigate the endogenous production of hydrogen sulphide in rat and human intrauterine tissues in vitro. Methods: The production of hydrogen sulphide in rat and human intrauterine tissues was measured in vitro using a standard technique. The expression of CBS and CSE was also investigated in rat and human intrauterine tissues via Western blotting. Furthermore, the effects of nitric oxide (NO) and low oxygen conditions on the production rates of hydrogen sulphide were investigated. Results: The order of hydrogen sulphide production rates (mean +/- SD, n = 4) for rat tissues were: liver (777 +/- 163 nM/min/g) > uterus (168 +/- 100 nM/min/g) > fetal membranes (22.3 +/- 15.0 nM/min/g) > placenta (11.1 +/- 4.7 nM/min/g), compared to human placenta (200 +/- 102 nM/min/g). NO significantly increased hydrogen sulphide production in rat fetal membranes (P < 0.05). Under low oxygen conditions the production of hydrogen sulphide was significantly elevated in human placenta, rat liver, uterus and fetal membranes (P < 0.05). Western blotting (n = 4) detected the expression of CBS and CSE in all rat intrauterine tissues, and in human placenta, myometrium, amnion and chorion. Conclusion: Rat and human intrauterine tissues produce hydrogen sulphide in vitro possibly via CBS and CSE enzymes. NO increased the production of hydrogen sulphide in rat fetal membranes. The augmentation of hydrogen sulphide production in human intrauterine tissues in a low oxygen environment could have a role in pathophysiology of pregnancy.